Fortress Biotech, Inc. (17)

Browse by Contract Category

Contracts

Asset Purchase Agreement entered into by and between Journey Medical Corporation and Dermira, Inc. dated as of March 31, 2021 (Filed With SEC on August 16, 2021)
Description of Securities of Fortress Biotech, Inc (Filed With SEC on March 31, 2021)
Amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan (Filed With SEC on June 19, 2020)
At Market Issuance Sales Agreement between the Company and Cantor Fitzgerald & Co., Oppenheimer & Co. Inc., H.C. Wainwright & Co., LLC, B. Riley FBR, Inc., and Dawson James... (Filed With SEC on May 29, 2020)
Asset Purchase Agreement entered into by and between Sentynl Therapeutics, Inc. and Cyprium Therapeutics, Inc. dated as of February 23, 2021 (Filed With SEC on August 16, 2021)
Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020 (Filed With SEC on August 16, 2021)
Asset Purchase Agreement entered into by and between Journey Medical Corporation and Dermira, Inc. dated as of March 31, 2021 (Filed With SEC on May 17, 2021)
Asset Purchase Agreement entered into by and between Sentynl Therapeutics, Inc. and Cyprium Therapeutics, Inc. dated as of February 23, 2021 (Filed With SEC on May 17, 2021)
Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020 (Filed With SEC on May 17, 2021)
Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020 (Filed With SEC on November 9, 2020)
Underwriting Agreement, dated August 26, 2020, by and among Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, Inc (Filed With SEC on August 28, 2020)
Underwriting Agreement, dated May 26, 2020, by and among Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, Inc (Filed With SEC on May 28, 2020)
Description of Securities of Fortress Biotech, Inc (Filed With SEC on March 16, 2020)
Underwriting Agreement, dated February 11, 2020, between Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, as... (Filed With SEC on February 12, 2020)
Underwriting Agreement, dated November 25, 2019, between Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, as... (Filed With SEC on November 26, 2019)
Development, Option and Stock Purchase Agreement dated January 30, 2019 by and among Fortress Biotech, Inc., Caelum Biosciences, Inc. (Caelum), Alexion Therapeutics, Inc., and the... (Filed With SEC on May 10, 2019)
Amended and Restated Consulting Agreement, entered into as of January 1, 2019, by and between the Registrant and Eric Rowinsky (Filed With SEC on March 18, 2019)